SAFETY DATA SHEET
Orbifloxacin Solid Formulation

SECTION 1. IDENTIFICATION

Product name : Orbifloxacin Solid Formulation
Other means of identification : No data available

Manufacturer or supplier’s details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
            Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Reproductive toxicity : Category 2

GHS label elements
Hazard pictograms :

Signal Word : Warning
Hazard Statements : H361d Suspected of damaging the unborn child.
Precautionary Statements :
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read
and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/
face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/
attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste dis-
posal plant.
SAFETY DATA SHEET

Orbifloxacin Solid Formulation

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>&gt;= 5 - &lt; 10</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
</tbody>
</table>

Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Suspected of damaging the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a
potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Nitrogen oxides (NOx)
- Metal oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for fire-fighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practices.
practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

**Engineering measures:**
- Use feasible engineering controls to minimize exposure to compound.
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

**Respiratory protection:**
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Particulates type
  - Hand protection Material: Chemical-resistant gloves

**Eye protection:**
- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection
Hygiene measures
- Work uniform or laboratory coat.
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Color</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
</tbody>
</table>
### SECTION 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>Not classified as a reactivity hazard.</td>
</tr>
<tr>
<td>Chemical stability</td>
<td>Stable under normal conditions.</td>
</tr>
<tr>
<td>Possibility of hazardous reactions</td>
<td>May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.</td>
</tr>
<tr>
<td>Conditions to avoid</td>
<td>Heat, flames and sparks. Avoid dust formation.</td>
</tr>
<tr>
<td>Incompatible materials</td>
<td>Oxidizing agents</td>
</tr>
<tr>
<td>Hazardous decomposition products</td>
<td>No hazardous decomposition products are known.</td>
</tr>
</tbody>
</table>

### SECTION 11. TOXICOLOGICAL INFORMATION

**Information on likely routes of exposure**
- Inhalation
- Skin contact
- Ingestion
- Eye contact

**Acute toxicity**
Not classified based on available information.

**Product:**
- Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
  Method: Calculation method

**Components:**

**Orbifloxacin:**
- Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg
  Remarks: No mortality observed at this dose. 
  LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular
LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular
LD50 (Rat): 233 mg/kg
Application Route: Intravenous
LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation
Not classified based on available information.

Components:

Orbifloxacin:
Species : Rabbit
Method : Draize Test
Result : No skin irritation

Magnesium stearate:
Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.
Components:

Orbifloxacin:
- **Species**: Rabbit
- **Result**: Mild eye irritation
- **Method**: Draize Test

Magnesium stearate:
- **Species**: Rabbit
- **Result**: No eye irritation
- **Remarks**: Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Orbifloxacin:
- **Test Type**: Maximization Test
- **Routes of exposure**: Dermal
- **Species**: Guinea pig
- **Result**: Not a skin sensitizer.

Magnesium stearate:
- **Test Type**: Maximization Test
- **Routes of exposure**: Skin contact
- **Species**: Guinea pig
- **Method**: OECD Test Guideline 406
- **Result**: negative
- **Remarks**: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

Orbifloxacin:
- **Genotoxicity in vitro**
  - **Test Type**: Bacterial reverse mutation assay (AMES)
    - Result: equivocal
  - **Test Type**: Mouse Lymphoma
    - Result: positive
  - **Test Type**: Chromosomal aberration
    - Test system: Human lymphocytes
    - Result: positive

    **Genotoxicity in vivo**
    - **Test Type**: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intraperitoneal injection
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment
: Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:
Genotoxicity in vitro
: Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Orbifloxacin:
Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Orbifloxacin:
Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects.

Effects on fetal development:

<table>
<thead>
<tr>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>Embryo-fetal toxicity: LOAEL: 333 mg/kg body weight</td>
</tr>
<tr>
<td>Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>General Toxicity Maternal: NOAEL: 20 mg/kg body weight</td>
</tr>
<tr>
<td>Embryo-fetal toxicity: NOAEL: 60 mg/kg body weight</td>
</tr>
<tr>
<td>Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Dog</td>
</tr>
<tr>
<td>Application Route: Oral</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 2.5 mg/kg body weight</td>
</tr>
<tr>
<td>Result: Effects on postnatal development, Skeletal malformations.</td>
</tr>
</tbody>
</table>

Reproductive toxicity - Assessment:

Some evidence of adverse effects on development, based on animal experiments.

**Magnesium stearate:**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test</td>
</tr>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Method: OECD Test Guideline 422</td>
</tr>
<tr>
<td>Result: negative</td>
</tr>
<tr>
<td>Remarks: Based on data from similar materials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on fetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Type: Embryo-fetal development</td>
</tr>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Result: negative</td>
</tr>
<tr>
<td>Remarks: Based on data from similar materials</td>
</tr>
</tbody>
</table>

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Not classified based on available information.
Repeated dose toxicity

**Components:**

**Orbifloxacin:**
Species: Rat
NOAEL: 20 mg/kg
LOAEL: 80 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: Testis, Liver, Kidney, spleen

Species: Mouse
NOAEL: 80 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 3 Months

Species: Juvenile dog
NOAEL: 50 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 14 Days
Target Organs: Heart, Bone
Symptoms: Gastrointestinal disturbance
Remarks: mortality observed

Species: Juvenile dog
NOAEL: 2 mg/kg
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 90 Days
Target Organs: Bone
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 30 Days

Species: Cat
NOAEL: 7.5 mg/kg
LOAEL: 22.5 mg/kg
Application Route: Oral
Exposure time: 1 Months
Symptoms: Gastrointestinal disturbance

**Magnesium stearate:**
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials
**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Orbifloxacin:**

Ingestion:
Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitzation.

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Magnesium stearate:**

- **Toxicity to fish**
  - LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
  - Exposure time: 48 h
  - Method: DIN 38412
  - Remarks: Based on data from similar materials

- **Toxicity to daphnia and other aquatic invertebrates**
  - EL50 (Daphnia magna (Water flea)): > 1 mg/l
  - Exposure time: 47 h
  - Test substance: Water Accommodated Fraction
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility.

- **Toxicity to algae/aquatic plants**
  - EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
  - Exposure time: 72 h
  - Test substance: Water Accommodated Fraction
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials
  - No toxicity at the limit of solubility.

  - NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
  - Exposure time: 72 h
  - Test substance: Water Accommodated Fraction
  - Method: OECD Test Guideline 201
  - Remarks: Based on data from similar materials

- **Toxicity to microorganisms**
  - EC10 (Pseudomonas putida): > 100 mg/l
  - Exposure time: 16 h
  - Test substance: Water Accommodated Fraction
  - Remarks: Based on data from similar materials
Persistence and degradability

Components:

Magnesium stearate:
Biodegradability : Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Magnesium stearate:
Partition coefficient: n-octanol/water : log Pow: > 4
Mobility in soil
No data available
Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

TDG
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:
AICS : not determined
SAFETY DATA SHEET
Orbifloxacin Solid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3</td>
<td>03/23/2020</td>
<td>801075-00011</td>
<td>09/13/2019</td>
<td>07/15/2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DSL</th>
<th>not determined</th>
</tr>
</thead>
<tbody>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

- **ACGIH**: USA. ACGIH Threshold Limit Values (TLV)
- **CA AB OEL**: Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
- **CA BC OEL**: Canada. British Columbia OEL
- **ACGIH / TWA**: 8-hour, time-weighted average
- **CA AB OEL / TWA**: 8-hour Occupational exposure limit
- **CA BC OEL / TWA**: 8-hour time weighted average
- **AICS**: Australian Inventory of Chemical Substances; **ANTT**: National Agency for Transport by Land of Brazil; **ASTM**: American Society for the Testing of Materials; **bw**: Body weight; **CMR**: Carcinogen, Mutagen or Reproductive Toxicant; **DIN**: Standard of the German Institute for Standardisation; **DSL**: Domestic Substances List (Canada); **ECx**: Concentration associated with x% response; **ELx**: Loading rate associated with x% response; **EmS**: Emergency Schedule; **ENCS**: Existing and New Chemical Substances (Japan); **ErCx**: Concentration associated with x% growth rate response; **ERG**: Emergency Response Guide; **GHS**: Globally Harmonized System; **GLP**: Good Laboratory Practice; **IARC**: International Agency for Research on Cancer; **IATA**: International Air Transport Association; **IBC**: International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; **IC50**: Half maximal inhibitory concentration; **ICAO**: International Civil Aviation Organization; **IECSC**: Inventory of Existing Chemical Substances in China; **IMDG**: International Maritime Dangerous Goods; **IMO**: International Maritime Organization; **ISHL**: Industrial Safety and Health Law (Japan); **ISO**: International Organisation for Standardization; **KECI**: Korea Existing Chemicals Inventory; **LC50**: Lethal Concentration to 50 % of a test population; **LD50**: Lethal Dose to 50% of a test population (Median Lethal Dose); **MARPOL**: International Convention for the Prevention of Pollution from Ships; **n.o.s.**: Not Otherwise Specified; **Nch**: Chilean Norm; **NO(A)EC**: No Observed (Adverse) Effect Concentration; **NO(A)EL**: No Observed (Adverse) Effect Level; **NOELR**: No Observable Effect Loading Rate; **NOM**: Official Mexican Norm; **NTP**: National Toxicology Program; **NZIoC**: New Zealand Inventory of Chemicals; **OECD**: Organization for Economic Co-operation and Development; **OPPTS**: Office of Chemical Safety and Pollution Prevention; **PBT**: Persistent, Bioaccumulative and Toxic substance; **PICCS**: Philippines Inventory of Chemicals and Chemical Substances; **(Q)SAR**: (Quantitative) Structure Activity Relationship; **REACH**: Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; **SADT**: Self-Accelerating Decomposition Temperature; **SDS**: Safety Data Sheet; **TCSI**: Taiwan Chemical Substance Inventory; **TDG**: Transportation of Dangerous Goods; **TSCA**: Toxic Substances Control Act (United States); **UN**: United Nations; **UNRTDG**: United Nations Recommendations on the Transport of Dangerous Goods; **vPvB**: Very Persistent and Very Bioaccumulative; **WHMIS**: Workplace Hazardous Materials Information System


Revision Date: 03/23/2020
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8